This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) Stock Moves -1.01%: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $586.46 in the latest trading session, marking a -1.01% move from the prior day.
Is SPDR MSCI USA StrategicFactors ETF (QUS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QUS
Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GSEW
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMV
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Eli Lilly (LLY) reachead $608.31 at the closing of the latest trading day, reflecting a -1.35% change compared to its last close.
Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain
by Zacks Equity Research
Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.
Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals
by Zacks Equity Research
Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.
Pharma Stock Roundup: LLY Meets IBD Study Goal, PFE, MRK Give Cancer Pipeline Updates
by Kinjel Shah
Eli Lilly's (LLY) mirikizumab meets the main goals in a Crohn's disease study. PFE, MRK and JNJ provide updates on cancer drugs in their pipeline.
The Zacks Analyst Blog Highlights Meta Platforms, Eli Lilly, Caterpillar, Citigroup and Micron Technology
by Zacks Equity Research
Meta Platforms, Eli Lilly, Caterpillar, Citigroup and Micron Technology are part of the Zacks top Analyst Blog.
Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study
by Zacks Equity Research
Eli Lilly's (LLY) Mounjaro is also being evaluated in clinical studies for patients who are obese or overweight and have CKD. Investors are probably expecting similar success with Mounjaro's CKD study.
Top Research Reports for Meta Platforms, Eli Lilly & Caterpillar
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Eli Lilly and Company (LLY) and Caterpillar Inc. (CAT).
Lilly (LLY) Moves 4.5% Higher: Will This Strength Last?
by Zacks Equity Research
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts
by Zacks Equity Research
A pharmacy benefit manager decides to place Lexicon's (LXRX) heart failure drug as a preferred product on Medicare national formularies on Nov. 1. The stock jumped 12% post this announcement.
The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer
by Zacks Equity Research
Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer are part of the Zacks top Analyst Blog.
Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus
by Kinjel Shah
The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates
by Kinjel Shah
Eli Lilly (LLY) offers to buy POINT Biopharma for approximately $1.4 billion. Sanofi (SNY) partners with Teva for co-developing immunology candidate.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
by Zacks Equity Research
Structure Therapeutics (GPCR) rises 9% on encouraging initial data from the early-stage study of its pipeline candidate, GSBR-1290, in healthy overweight or obese individuals.
Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Eli Lilly (LLY) concluded the recent trading session at $531.46, signifying a +1.19% move from its prior day's close.
ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data
by Zacks Equity Research
Interim data from a mid-stage study shows that a combination regimen of ALX Oncology's (ALXO) lead candidate achieved 52% ORR in certain gastric cancer patients.